SCHEMBL3365281

SCHEMBL3365281

Oc1ccccc1N=Cc1ccc(-c2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.49
CA2 P00918 2/20 0.49
CA9 Q16790 2/20 0.49
CA1 P00915 1/20 0.49
MAPT P10636 7/20 0.49
MEN1 O00255 6/20 0.49
KMT2A Q03164 6/20 0.49
LMNA P02545 6/20 0.49
GAA P10253 5/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
HTT P42858 4/20 0.49
TSHR P16473 1/20 0.49
HSD17B10 Q99714 1/20 0.49
KDM4E B2RXH2 7/20 0.46
ALDH1A1 P00352 6/20 0.46
ATM Q13315 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
NPC1 O15118 2/20 0.45
POLB P06746 2/20 0.45
TP53 P04637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL802770 1.00 CA12 (0.49) CA12CA2CA9CA1MAPT
SCHEMBL14982912 0.90 CA12 (0.57) CA12CA2CA9MAPTMEN1
SCHEMBL1238795 0.88 CA2 (0.55) CA12CA2CA9CA1MAPT
SCHEMBL2322410 0.88 CA2 (0.55) CA12CA2CA9CA1MAPT
SCHEMBL30373259 0.88 CA2 (0.55) CA12CA2CA9CA1MAPT
SCHEMBL14337533 0.88 CA2 (0.55) CA12CA2CA9CA1MAPT
Lithium Ion SCHEMBL3400785 0.86 CA2 (0.53) CA12CA2CA9CA1MAPT
SCHEMBL4601928 0.85 CA2 (0.52) CA12CA2CA9CA1MAPT
SCHEMBL29690204 0.85 CA2 (0.52) CA12CA2CA9CA1MAPT
SCHEMBL4601929 0.85 CA2 (0.52) CA12CA2CA9CA1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120205638-A1 ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER MERCK PATENT GMBH (DE) 2012-08-16 US disclosed
EP-2095690-B1 ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER MERCK PATENT GMBH (DE) 2010-10-13 EP disclosed
EP-2095690-A1 ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER MERCK PATENT GmbH (DE) 2009-09-02 EP disclosed
WO-2008081178-A1 ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER MERCK PATENT GMBH (DE) 2008-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120205638-A1 ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER ACSL3, APOL1, INTS9 CA12 4003/4885CA2 2621/4885CA9 2356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.